Details
Decris Indications
Additions to the standard treatment with beta blockers to reduce the risk of morbidity and mortality associated with cardiovascular disease in stable patients with left ventricular dysfunction (ejection fraction ≤ 40%) and clinical signs of heart failure after recent myocardial myocardial infarction.
Addition to standard optimal therapy to reduce the risk of morbidity and mortality associated with cardiovascular diseases in adult patients with heart failure class II (chronic) NYHA classification and left ventricular dysfunction (ejection fraction ≤ 30%).
Contraindications
Hypersensitivity to eplerenone or to any of the excipients.
The level of potassium in the blood serum> 5 mmol / L at the start of treatment.
Renal failure severe (estimated glomerular filtration rate <30 mL / min / 1.73 m2).
Severe hepatic insufficiency (class C on a scale Child - Pugh).
Concomitant use of potassium-sparing diuretics, potassium or drugs potent inhibitors of CYP3A4 (eg, itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodone).
Concomitant use of eplerenone in triple combination with ACE inhibitors and angiotensin receptor blockers.
Dosage & Administration
Tablets containing the drug dose of 25 mg or 50 mg. The maximum daily dose is 50 mg per day.
Eplerenone can be taken with food, and regardless of the meal.
Patients with heart failure after myocardial infarction. The recommended maintenance dose of eplerenone is 50 mg 1 time a day. Treatment should be initiated at a dose of 25 mg 1 time per day and gradually increase to the target dose of 50 mg 1 time a day. It is desirable to achieve the target dose for 4 weeks, given the level of potassium in the blood serum (see table below). Treatment usually eplerenone should begin by 3-14 days after acute myocardial infarction.